FindTrial
Sign In

Clinicopathologic features of long-term survivors of immunotherapy for esophageal cancer: A Multicenter retrospective study

Clinicopathologic features of long-term survivors of immunotherapy for esophageal cancer: A Multicenter retrospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112434
Enrollment
Unknown
Registered
2025-11-13
Start date
2024-03-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

observation group:None

Sponsors

First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18; 2. Patients with advanced esophageal cancer; 3. After immunotherapy, the overall survival was more than 24 months 4. Provide complete pathological data and clinical records related to immunotherapy.

Exclusion criteria

Exclusion criteria: 1.Lack of follow-up information; 2. Severe organ dysfunction before immunotherapy; 3. Double primary cancer; 4. Lack of complete clinical data and pathological information.

Design outcomes

Primary

MeasureTime frame
overall survival;—

Secondary

MeasureTime frame
Treatment mode;Age;gender;Tumor stage;Type of pathology;History of smoking;History of alcohol consumption;Family History;Past History;Tumor location;—

Countries

China

Contacts

Public ContactDao Xin

First Affiliated Hospital of Zhengzhou University

xd105982@163.com+86 130 4105 1932

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026